|
Atomistry » Chlorine » PDB 4yli-4ywy » 4ytf | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atomistry » Chlorine » PDB 4yli-4ywy » 4ytf » |
Chlorine in PDB 4ytf: Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune DiseasesEnzymatic activity of Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases
All present enzymatic activity of Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases:
2.7.10.2; Protein crystallography data
The structure of Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases, PDB code: 4ytf
was solved by
L.Farmer,
M.W.Ledeboer,
H.J.Zuccola,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Other elements in 4ytf:
The structure of Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases also contains other interesting chemical elements:
Chlorine Binding Sites:
The binding sites of Chlorine atom in the Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases
(pdb code 4ytf). This binding sites where shown within
5.0 Angstroms radius around Chlorine atom.
In total only one binding site of Chlorine was determined in the Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases, PDB code: 4ytf: Chlorine binding site 1 out of 1 in 4ytfGo back to![]() ![]()
Chlorine binding site 1 out
of 1 in the Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase (Jak) 3 Inhibitor For the Treatment of Autoimmune Diseases
![]() Mono view ![]() Stereo pair view
Reference:
L.J.Farmer,
M.W.Ledeboer,
T.Hoock,
M.J.Arnost,
R.S.Bethiel,
Y.L.Bennani,
J.J.Black,
C.L.Brummel,
A.Chakilam,
W.A.Dorsch,
B.Fan,
J.E.Cochran,
S.Halas,
E.M.Harrington,
J.K.Hogan,
D.Howe,
H.Huang,
D.H.Jacobs,
L.M.Laitinen,
S.Liao,
S.Mahajan,
V.Marone,
G.Martinez-Botella,
P.Mccarthy,
D.Messersmith,
M.Namchuk,
L.Oh,
M.S.Penney,
A.C.Pierce,
S.A.Raybuck,
A.Rugg,
F.G.Salituro,
K.Saxena,
D.Shannon,
D.Shlyakter,
L.Swenson,
S.K.Tian,
C.Town,
J.Wang,
T.Wang,
M.W.Wannamaker,
R.J.Winquist,
H.J.Zuccola.
Discovery of Vx-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor For the Treatment of Autoimmune Diseases. J.Med.Chem. V. 58 7195 2015.
Page generated: Fri Jul 11 23:29:38 2025
ISSN: ISSN 0022-2623 PubMed: 26230873 DOI: 10.1021/ACS.JMEDCHEM.5B00301 |
Last articlesF in 4L45F in 4L44 F in 4L43 F in 4L42 F in 4L3L F in 4L3J F in 4L2O F in 4L2G F in 4KZL F in 4KZD |
© Copyright 2008-2020 by atomistry.com | ||
Home | Site Map | Copyright | Contact us | Privacy |